MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.
Laurence Albigès(Université Paris-Saclay), Sabina Signoretti(Brigham and Women's Hospital), Lone H. Ottesen(AstraZeneca (United Kingdom)), Anders Mellemgaard(AstraZeneca (United Kingdom)), Toni K. Choueiri(Harvard University), Jae‐Lyun Lee(Ulsan College), Anne L’Hernault(AstraZeneca (United Kingdom)), Jonathan Wessen(AstraZeneca (United Kingdom)), Stephen Walker(AstraZeneca (United Kingdom)), Mathilde Cancel(Centre Hospitalier Universitaire de Tours), Daniel Yick Chin Heng(University of Calgary), Melanie M. Frigault(Vifor Pharma (United States))
Cited by 4
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k